EGFR and cancer: As previously alluded to, some EGFR-targeting antibodies, approved for the use in patients with mCRC and SCCHN, not only inhibit ligand-induced EGFR activity and signaling, but also elicit ADCC through the interaction between their IgG1 Fc region and the FcγR-expressing effector cells, typically NK cells, leading to the destruction of EGFR-expressing cancer cells (148, 217).